Condensed Consolidated Statements of Cash Flow (Unaudited) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2025	Jun. 30, 2024
OPERATING ACTIVITIES
Net Income (Loss)	$ (22,003)	$ (37,671)
Non-cash items:
Depreciation	341	711
Loss on impairment of leasehold improvements and lab equipment	2,811	0
Stock-based compensation expense	4,428	5,194
Change in fair value of contingent consideration	559	391
Non-cash royalty revenue	(974)	(1,164)
Non-cash interest expense	55	70
Net accretion and amortization of investments in marketable securities	(1,386)	(1,229)
Net change in operating items:
Accounts receivable	1,384	9
Prepaid expenses and other assets	(640)	(40)
Accounts payable and accrued liabilities	(3,056)	837
Change in deferred license revenue	(10,434)	(757)
Other liabilities	(225)	(150)
Net cash used in operating activities	(29,140)	(33,799)
INVESTING ACTIVITIES
Purchase of investments in marketable securities	(63,214)	(57,982)
Proceeds from sale of property and equipment	9	0
Disposition of investments in marketable securities	90,165	79,601
Acquisition of property and equipment	0	(96)
Net cash provided by investing activities	26,960	21,523
FINANCING ACTIVITIES
Issuance of common shares pursuant to the Open Market Sale Agreement	0	44,124
Issuance of common shares pursuant to exercise of stock options	3,106	4,465
Issuance of common shares pursuant to ESPP	131	211
Net cash provided by financing activities	3,237	48,800
Effect of foreign exchange rate changes on cash and cash equivalents	25	(21)
Increase in cash and cash equivalents	1,082	36,503
Cash and cash equivalents, beginning of period	36,330	26,285
Cash and cash equivalents, end of period	$ 37,412	$ 62,788